Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED

NCT ID: NCT06167733

Last Updated: 2025-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-29

Study Completion Date

2025-10-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adult subjects with mild to moderate and moderate ED who meet the study eligibility criteria will be enrolled in the study. The enrolled subjects will be randomized by a 1:1 ratio to receive the Active or Sham VERTICA® treatment. Baseline assessments will include collection of demographic data, medical history, concomitant medications and baseline clinical examinations. The initial treatment session will be performed in a clinical setting simulating home use to determine proper device use and to evaluate device tolerability, followed by continued home use of the device for a total of 6 months. Patients will be instructed to attempt sexual activity periodically over the course of the study. Every time a sexual intercourse is attempted, the patient will be requested to complete an event log using validated assessments. Patients will present for monthly follow-up visits, during which safety will be evaluated and additional efficacy assessments will be performed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erectile Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Active vs. Sham
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Study personnel, including the investigator and raters and study subjects will be blinded to the treatment assignment (active vs. sham)

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

Group Type EXPERIMENTAL

VERTICA Active device

Intervention Type DEVICE

VERTICA device with a therapeutic RF energy level

Sham

Group Type SHAM_COMPARATOR

VERTICA Sham device

Intervention Type DEVICE

VERTICA device with a low, non-therapeutic RF energy level

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VERTICA Active device

VERTICA device with a therapeutic RF energy level

Intervention Type DEVICE

VERTICA Sham device

VERTICA device with a low, non-therapeutic RF energy level

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult, heterosexual, males between 22 and 85 years of age
* Subjects diagnosed with organic ED for at least 3 months, according to the American Urology Association (AUA) Guideline Statement 1 (as described in Section 8.1.1 of the study protocol).
* Subjects with an IIEF-EF score between 11-21
* Steady relationship for at least 3 months
* Subject is sexually active, with at least weekly sexual intercourse attempts or 6 times a month
* Subject is willing to sign informed consent and follow study protocol procedures
* Subject has a smartphone

Exclusion Criteria

* Castrate and late onset hypogonadism
* History of Priapism or Peyronie's Disease
* Surgery or radiotherapy of the pelvic region
* Anatomic penile deformations or penile prosthesis
* Treatment with antiandrogens
* Previous whole gland treatment of the prostate (Cryoablation, HIFU, external beam radiation of seed implantation, Radical prostatectomy any approach, etc.)
* History of urothelial or colorectal cancer
* Major neurological conditions such as Alzheimer's, Parkinson, Multiple sclerosis, ALS, spinal cord injury, pelvic neuropathy
* Evidence of neurogenic bladder or an indwelling Foley catheter or clean intermittent catheterization (CIC) within 30 days
* Subjects who are taking anticoagulation or anti-platelet therapy
* History of psychiatric disorders, premature ejaculation and drug or alcohol abuse
* Subjects who are incarcerated
* Subjects who are cognitively challenged
* Serious heart or lung disease
* Pregnant partner
Minimum Eligible Age

22 Years

Maximum Eligible Age

85 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

OHH-MED Medical Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California, Irvine Medical Center

Newport Beach, California, United States

Site Status COMPLETED

San Diego Sexual Medicine

San Diego, California, United States

Site Status RECRUITING

Optimal Health Miami

Aventura, Florida, United States

Site Status RECRUITING

The University of Chicago

Chicago, Illinois, United States

Site Status WITHDRAWN

Rachel Rubin MD

Bethesda, Maryland, United States

Site Status RECRUITING

Cleveland Clinic

Cleveland, Ohio, United States

Site Status RECRUITING

Baylor College of Medicine

Houston, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ahava Stein

Role: CONTACT

1-888-443-3867

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sue Goldstein

Role: primary

619-265-8865

Sayonara Nunez

Role: primary

305-466-9000

Sarina Hanfling

Role: primary

202-888-6731

Fiona Wardrop

Role: backup

Lauren Grimm

Role: primary

216-444-4650

Carmen Czich

Role: backup

216-444-5081

Haarika Gudlavalleti

Role: primary

832-474-8009

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

URN-2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Erectile Dysfunction Treatment Using Stem Cells
NCT06550752 NOT_YET_RECRUITING PHASE1/PHASE2
PRP for Treatment of Peyronie's Disease
NCT04512287 COMPLETED PHASE2